FindTrial
Sign In

Gardasil®9

BIOLOGICAL7 trials

Sponsors

Xiamen University, Sinocelltech Ltd., Massachusetts General Hospital, Merck Sharp & Dohme LLC

Conditions

Cervical CancerCondylomata AcuminataHPV Infection Vaccine Safety SCT1000HealthyHivHuman Papilloma VirusInterventionalPrevention

Phase 1

A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years
NCT04921111
Sinocelltech Ltd.HPV Infection Vaccine Safety SCT1000
Start: 2021-07-02End: 2022-10-31Target: 240Updated: 2021-09-17
A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
Active, not recruitingNCT06688058
Merck Sharp & Dohme LLCHealthy
Start: 2024-12-20End: 2026-11-30Target: 72Updated: 2026-03-13

Phase 2

A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years
NCT05060484
Sinocelltech Ltd.Interventional, Prevention, Randomized
Start: 2021-10-19End: 2022-07-31Target: 1800Updated: 2021-10-28
A Clinical Study of V540A in Healthy Female Participants (V540A-005)
WithdrawnNCT07224477
Merck Sharp & Dohme LLCHealthy
Start: 2026-07-20End: 2028-04-04Updated: 2026-09-14

Phase 3

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
CompletedNCT04782895
Xiamen UniversityCervical Cancer, Condylomata Acuminata
Start: 2021-03-14End: 2022-07-25Updated: 2023-06-15

Phase 4

Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
Active, not recruitingNCT06436274
Massachusetts General HospitalHiv, Human Papilloma Virus
Start: 2024-10-14End: 2027-06-30Updated: 2026-01-12

Unknown Phase

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
Active, not recruitingNCT06197802
Xiamen UniversityCervical Cancer, Condylomata Acuminata
Start: 2023-12-30End: 2025-09-01Target: 392Updated: 2025-07-31

Related Papers

Immunogenicity comparison of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial.
2025-08-27
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
2023-07-1728 citations